ID   MZ-MEL-13
AC   CVCL_B286
SY   MZ-Mel-13; Mz-Mel-13; MZ MEL 13; MZ Mel 13; MZ13-MEL
DR   cancercelllines; CVCL_B286
DR   Cosmic; 972268
DR   Cosmic; 2163795
DR   ESTDAB; ESTDAB-052
DR   Wikidata; Q54907219
RX   PubMed=15592718;
RX   PubMed=23851445;
CC   HLA typing: A*02:01; B*27:04,18:01; C*04:01:01,07:01:01; DPB1*04:01; DQB1*03:01:01; DRB1*11:03:01,04:01:01 (PubMed=15592718).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445).
ST   Source(s): ESTDAB=ESTDAB-052
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 11,12
ST   D3S1358: 16,18
ST   D5S818: 12
ST   D7S820: 10,12
ST   FGA: 21
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 17,19
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 16
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5; PMCID=PMC11032966;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A.,
RA   Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//